Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 26 - 30 of 30 in total
Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 . Crotalus atrox antivenin...
Approved
Experimental
Matched Description: … Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide ... isolating the antivenin of interest through fractionation and chromatography techniques. ... The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F113]. …
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran.[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects...
Approved
Matched Description: … Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin
Matched Categories: … Blood and Blood Forming Organs …
Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect. Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S....
Approved
Investigational
Matched Description: … ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs …
Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing...
Investigational
Matched Description: … It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome …
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity. ... Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. ... Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs …
Displaying drugs 26 - 30 of 30 in total